

CRISPR: the next frontier in biotechnology

CRISPR, the technology that allows us to edit the genes of living organisms is rapidly developing and it has the potential to be a technology as revolutionary as the first computers when they were introduced 40 years ago.

In this session we will review the latest developments concerning CRISPR, with leading international companies such as Merck Millipore, with one of the largest CRISPR-related patent portfolio worldwide and local Spanish companies such as ZeClinics, that applies this technology to zebrafish to alter gene transcription and function, and Integra Therapeutics, that combines the precision of CRISPR with the gene transfer efficiency of viral integrases and transposases making their technology more stable and precise.

The panel will also address what CRISPR has in store for us and what can we expect of this exciting technology that will revolutionize our industry forever.

Moderator:

- **Judith Anido**, CEO, CataloniaBio (Spain)

Speakers:

- **Javier Terriente**, CEO, ZeClinics (Spain)
- **Graeme Garvey**, Head of Genome Engineering R&D, MilliporeSigma (USA)
- **Avencia Sanchez-Mejías**, CEO, Integra Therapeutics (Spain)